BioCryst Initiates Enrollment in Pivotal Trial of Forodesine HCL in Patients with Cutaneous T-Cell Lymph... (provide data to establish forodesine HCL...)

BioCryst Initiates Enrollment in Pivotal Trial of Forodesine HCL in Patients with Cutaneous T-Cell Lymphoma (CTCL)

Date:10/12/2007

provide data to establish forodesine HCL as a new treatment alternative for CTCL patients who have not responded to currently available therapies."

"Initiation of this pivotal trial is a great step forward toward our goal of getting our late-stage pipeline products to market," said Jon P. Stonehouse, President and Chief Executive Officer of BioCryst.

Forodesine HCL is a transition-state analog inhibitor of the target enzyme purine nucleoside phosphorylase (PNP). In addition to CTCL, the drug is currently being studied in clinical trials for indications including T and B- cell leukemia (T-ALL, B-ALL), and chronic lymphocytic leukemia (CLL).

About BioCryst

BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential commercialization including forodesine HCL in oncology, BCX-4208 in transplantation and autoimmune diseases and peramivir in seasonal and life- threatening influenza. BioCryst has a worldwide partnership with Roche for the development and commercialization of BCX-4208, and is collaborating with Mundipharma for the development and commercialization of forodesine HCL in markets across Europe, Asia, Australia and certain neighboring countries. In January, 2007 the U.S. Department of Health and Human Services (DHHS) awarded a $102.6 million, four-year contract to BioCryst for advanced development of peramivir to treat seasonal and life-threatening influenza. In February 2007 BioCryst established a partnership with Shionogi & Co., to develop and commercialize peramivir in Japan. For more information about BioCryst, please visit the company's web site at http://www.biocryst.com.

Forward-looking statements

This press release contains forwar
'/>"/>

SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4
Related medicine technology :

1. BioCryst Presents Phase I Peramivir Data at the Options for the Control of Influenza Conference
2. Malvern initiates European user group meetings for chemical imaging
3. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
4. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
5. Celsion Completes Enrollment in Phase I Liver Cancer Study
6. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
7. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
8. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
9. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
10. Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia Clinical Trial
11. Javelin Pharmaceuticals Announces Successful Pivotal Phase 3 Trial Data

Post Your Comments:

(Date:11/20/2009)... , PLYMOUTH MEETING, Pa., Nov. 20 /PRNewswir... Times article that questions why currently avail...e cancers are being ignored, ECRI Institute, an in...admap to the evidence on Finasteride for Preventi...The November 13, 2009, New York Times article, "...

(Date:11/20/2009)..., MEMPHIS, Tenn., Nov. 20 /PRNewswire-FirstCa...dics Division is pleased to announce the signing o...d States Department of Defense that may lead to th...to revolutionize the treatment of the limbs of sol... year, the Defense Advanced Research Projects Agen...

(Date:11/19/2009)... , ARDEE, Ireland, Nov. 19 War...the pricing of its previously announced secondary ... price to the public of $22.25 per share. The sel...in Capital Partners, DLJ Merchant Banking, J.P. Mo... H. Lee Partners, L.P., certain other institutiona...

Breaking Medicine Technology:ECRI Institute Releases Roadmap to the Evidence on Finasteride for Prevention of Prostate Cancer: New Hotline Report to Aid Healthcare Decision Makers and Journalists 2 ECRI Institute Releases Roadmap to the Evidence on Finasteride for Prevention of Prostate Cancer: New Hotline Report to Aid Healthcare Decision Makers and Journalists 3 Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries 2 Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries 3 Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries 4 Warner Chilcott Prices Secondary Equity Offering 2 Warner Chilcott Prices Secondary Equity Offering 3 Warner Chilcott Prices Secondary Equity Offering 4 CEM Wins Presidential Green Chemistry Challenge Award for the Sprint Rapid Protein Analyzer 12724 1 CEM Wins Presidential Green Chemistry Challenge Award for the Sprint Rapid Protein Analyzer 12724 2 KV Pharmaceutical Receives Letter From NYSE Regarding Delayed Filing of Its 2009 Annual Report on Form 10 K 49600 1 KV Pharmaceutical Receives Letter From NYSE Regarding Delayed Filing of Its 2009 Annual Report on Form 10 K 49600 2 KV Pharmaceutical Receives Letter From NYSE Regarding Delayed Filing of Its 2009 Annual Report on Form 10 K 49600 3 KV Pharmaceutical Receives Letter From NYSE Regarding Delayed Filing of Its 2009 Annual Report on Form 10 K 49600 4 KV Pharmaceutical Receives Letter From NYSE Regarding Delayed Filing of Its 2009 Annual Report on Form 10 K 49600 5 KV Pharmaceutical Receives Letter From NYSE Regarding Delayed Filing of Its 2009 Annual Report on Form 10 K 49600 6 New Strategy Eyed for AIDS Treatment 49598 1 New Strategy Eyed for AIDS Treatment 49598 2

[0] ECRI Institute Releases Roadmap to the Evidence on Finasteride for Prevention of Prostate Cancer: New Hotline Report to Aid Healthcare Decision Makers and Journalists [0] Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries [0] Warner Chilcott Prices Secondary Equity Offering

...itor, and R7128, nucleoside polymerase inhibitor, ...n patients with hepatitis C - , , NUTLEY, N.J., ...oche, InterMune, Inc. (Nasdaq: ITMN ) and Pharma...esults from their innovative, interferon-free regi...herapy for the treatment of patients chronically i...

...rmed to date will be presented during the Internat...nnual Meeting in Paris, France on April 24, 2009 ...d as an in vitro assessment of cell-mediated imm...erous clinical investigations have contributed to ...g recipients of solid organ transplants. , , (Lo...

Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen An Independent Study Reports on the Utility of ImmuKnow(R), the Cylex(TM) Immune Cell Function Assay, for Monitoring Heart Transplant Recipients

(Date:11/20/2009)... The American Academy o... care reform legislation released this week to con...e individual coverage mandate. The actuaries said ...imize adverse selection stemming from more restric.... ,, "The individual mandate language should be...

(Date:11/20/2009)...s and Congressmen in Competitive Re-election Battl... , Washington, DC (Vocus)...ning for re-election next year in races deemed to ... come to regret voting for House Speaker Nancy Pel...ing Zogby International/ O’Leary Report pol...

(Date:11/20/2009)... Centene Corporation (N...at the Bank of America Merrill Lynch 2009 Credit C...rowne Plaza Hotel Times Square in New York City. ,...at 8:30 a.m. Eastern Time. Investors and other int...f Centene,s presentation at: http://www.veracast....

(Date:11/20/2009)...ewswire-USNewswire/ -- The following is a statemen...da Health Care Association: ,, "The Nevada Heal...ate Majority Leader Harry Reid for his leadership ... of protecting every Nevada seniors, ongoing acces... strength and viability of our state,s vital front...

(Date:11/20/2009)...ormaldehyde used for embalming in the funeral indu...th from myeloid leukemia, according to a new study...he National Cancer Institute . , Previous studie...etic malignancies and brain cancer in anatomists, ... whom may have worked with formaldehyde. , For...

Breaking Medicine News(10 mins):Health News:Actuaries to Senate: Strengthen Individual Mandate 2 Health News:Just 25% of Voters in Competitive 2010 Senate Races “Much More Likely” to Support Pelosi-Democrats Who Voted for Health Care Bill 2 Health News:Just 25% of Voters in Competitive 2010 Senate Races “Much More Likely” to Support Pelosi-Democrats Who Voted for Health Care Bill 3 Health News:Funeral industry workers exposed to formaldehyde face higher risk of leukemia 2

[0] Actuaries to Senate: Strengthen Individual Mandate [0] Just 25% of Voters in Competitive 2010 Senate Races “Much More Likely” to Support Pelosi-Democrats Who Voted for Health Care Bill [0] Centene Corporation to Present at Bank of America Merrill Lynch Credit Conference [0] Nevada Health Care Association (NHCA) Supports Majority Leader Reid [0] Funeral industry workers exposed to formaldehyde face higher risk of leukemia

...n,(Nasdaq: MDTH ), a healthcare provider focused ...the diagnosis and treatment of cardiovascular,dise... first fiscal,quarter, which ended December 31, 20...). As part of the,recapitalization, MedCath,s owne...

...ploying,cross- functional, yet sufficiently specia...g leaders at pharmas and biotechs. However,best-in... similar,structure, composition, and responsibilit...have a core team of three,to 10 people and 86 perc...

...RAXIS Health Inc. (TSX:,DAX); (Nasdaq: DRAX ) rep...,the year ended December 31, 2007. Results for the...rter of 2006 were impacted by lower product sales,...th quarter of 2007 relative to the same quarter in...

...) Research Proves Dance Dance Revolut... Feb. 7 Based on the growing popularity of,video ... in favor of more,full-body interaction, the Ameri...sse, focused on quantifying DDR,s potential physic...

...asdaq: NUVO ) today announced that it will hold t...estor Conference February 13, 2008 11:45 a.m. ...ww.corporate-ir.net/ireye/conflobby.zhtml?ticker=N... ET (1:30 p.m. PT) Dr. Ted W. Love, Chairman and ...

...r and Health Advocates Together to Educate Co...SOUTHBOROUGH, Mass., Feb. 7 Most Americans are aw...id you know the Environmental,Protection Agency sa... out of 10 Americans are unaware of this fact,prim...

MedCath Corporation Reports First Quarter Earnings Pharmaceutical Product Commercialization & Governance Best Practices: Securing Talent for Highly-Effective Brand Teams DRAXIS Health Reports Fourth Quarter and Year End Results Can a Video Game Make Your Kids More Fit?Nuvelo Announces Upcoming Conference Calls, Webcasts and Conference Participation February is Designated as 'National Care About Your Indoor Air' Month

Bipolar Bayonet Forceps

Elmed Extra Long Straight Bipolar Forceps

Micro Forceps

Bi-Co-Matic Handswitching Bipolar Micro Forceps with Elmed Fitting, Insulated

Medicine Products:

Bipolar Bayonet Forceps Elmed Extra Long Straight Bipolar Forceps Micro Forceps Bi-Co-Matic Handswitching Bipolar Micro Forceps with Elmed Fitting, Insulated

BioCryst Initiates Enrollment in Pivotal Trial of Forodesine HCL in Patients with Cutaneous T-Cell Lymph...(provide data to establish forodesine HCL...),Health